Jiuzhitang Co., Ltd.

Founded in March 2018, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (“Jiuzhitang Maker”) is a biotechnology company focused on the manufacture, R&D and sales of stem cell-based drugs and regenerative care products. Jiuzhitang Maker was established with an investment of 200 million yuan made by Yonghe Qihang Fund launched by Jiuzhitang Co., Ltd. (“Jiuzhitang”, stock code: sz000989).

Jiuzhitang Maker has built a large-scale stem cell drugs R&D and manufacturing facility that meets Chinese, US and EU cGMP standards in Beijing’s Daxing Biomedicine Industry Park, known as the Chinese Medicine Valley. With the production and office area totalling about 4500m2, the facility has four separate Grade B+A clean areas dedicated to the manufacture of clinical grade stem cell drugs that comply with Chinese and US drug application requirements.

By importing Stemedica’s world leading BioSmart technology platform characterized by proprietary hypoxic manufacturing environment, Jiuzhitang Maker has acquired the core technology that holds key to the scalable, standardized and traceable production of clinical grade stem cell products. The output of stem cell products prepared through this US cGMP compliant platform ranks NO.1 in the world with no compromise to product safety and efficacy. This unique advantage has successfully resolved the technical challenges involved in making stem cells into drugs.

Jiuzhitang Maker has been selected as one of the Top 10 Key Enterprises by the Development and Reform Commission of Daxing District and the management committee of the Biomedicine Industry Park, and have been awarded titles including “ZGC High-Tech Enterprise”, “National High-Tech Enterprise”, “ZGC Gold Seed Enterprise” and “Postdoctoral Station”. “A Pre-clinical Study Using Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat Acute Cerebral Stroke” and “Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Lung Injuries Caused by COVID-19”, two research projects JZT Maker plans to launch were both approved by relevant authorities, and received fund support from Beijing Science and Technology Major Project initiative, Daxing District Program for Better Development of the Healthcare Industry, the COVID-19 Epidemic Prevention and Control project under Daxing Science and Technology Commission initiative and Daxing District Program for Advancing Transfer and Transformation of Technological Achievements.

Jiuzhitang Maker’s Investigational New Drug application for the MSC product was approved in February 2020 (Acceptance No.: JXSL1900126). Maker’s IND approval bears symbolic significance to the development of China’s stem cell industry as the clinical trial Maker intends to launch is the first CDE-approved study using an imported stem cell product, the first clinical program treating a major neurological indication with stem cells, and the first study evaluating bone marrow-derived mesenchymal stem cells after CDE resumes accepting applications for stem cell clinical trials. Officially initiated on January 12, 2021, this clinical trial (ASSIST) is underway at a number of hospitals including Beijing Tiantan Hospital affiliated to Capital Medical University.

By adhering to JZT’s ancestral motto "Make All Efforts As a Drug Developer; Devote Conscience As a Healer” that has been passing on for over 370 years, Jiuzhitang Maker will seek to create efficient synergy between resources and technology and promote the early availability of stem cell drugs on the domestic market by leveraging the research basis and manufacturing technology of our US partner company and the technological upgrading and industrialization capability unique to China.

Jiuzhitang Maker

Founded in March 2018, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (“Jiuzhitang”) is a biotechnology company focused on the manufacture, R&D and sales of stem cell-based drugs and regenerative care products. Jiuzhitang Maker was established with an investment of 200 million yuan made by Yonghe Qihang Fund initiated by Jiuzhitang Co., Ltd. (“Jiuzhitang”, stock code: sz000989).

Jiuzhitang Maker built a large-scale allogenic stem cells R&D and manufacturing facility that meets Chinese, US and EU cGMP standards in ZGC Biomedicine Industry Park, Daxing District, the first of its kind in Beijing. Covering an area approximating 4500m2, the facility has 4 separate Grade B+A clean areas dedicated to the manufacture of clinical grade stem cell products compliant with Chinese and US drug application requirements.

By importing Stemedica’s world leading BioSmart technology platform characterized by proprietary hypoxic manufacturing environment, Jiuzhitang Maker will acquire the core technology that holds key to the scalable, standardized and traceable production of clinical grade stem cell products. The output of stem cell products achieved by this US cGMP compliant platform ranks NO.1 in the world with no compromise to product safety and efficacy. This unique advantage successfully solved the technical challenges involved in making stem cells into drugs.

Jiuzhitang Maker has been selected as one of the Top 10 Key Enterprises by the Development and Reform Commission of Daxing District and the management committee of the Biomedicine Industry Park, and have been awarded titles including “ZGC High-Tech Enterprise”, “National High-Tech Enterprise” and “ZGC Gold Seed Enterprise”. “A Pre-clinical Study Using Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat Acute Cerebral Stroke” and “Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Lung Injuries Caused by COVID-19”, two research projects JZT Maker plans to launch were both approved by relevant authorities, and received fund support from Beijing Science and Technology Major Project initiative, Daxing District Program for Better Development of the Healthcare Industry, and funding provided by a Daxing Science and Technology Commission initiative to COVID-19 epidemic prevention and control projects.

Jiuzhitang Maker received IND approval for stem cell therapy in February 2020. The clinical trial Maker intends to launch is the first CDE-approved study using an imported stem cell product, the first study treating a major neurological indication with stem cells, and the first study evaluating bone marrow-derived mesenchymal stem cells since National Medical Products Administration resumed review of IND applications for stem cell therapy.

Looking into the future, Jiuzhitang Maker will work tirelessly to shorten the time needed to launch stem cell drugs in the domestic market, and further satisfy humankind’s multi-level and multi-aspect health needs by utilizing forefront achievements made in studies into regenerative medicine.

Stemedica Cell Technologies, Inc.

Founded in 2005, Stemedica Cell Technologies, Inc. is one of the world’s few corporations that are capable of manufacturing both human bone marrow-derived mesenchymal stem cells and human neural stem cells. Through 15 years’ development since establishment, Stemedica has created a proprietary hypoxic stem cells production platform named BioSmart, which is able to realize a manufacturing capacity significantly greater than most of its competitors. Stemedica and its partners have published 15 high-impact research papers and filed application for 26 patents, among which 7 have been approved so far.

Secretion of cytokines, homing and tissue repair capabilities, and responses to inflammation demonstrated by Stemedica’s stem cells are remarkably superior to stem cells cultured under normal conditions, which enables the company to be selected as “Best-in-Class” supplier of stem cells by Life Technologies. Stemedica has launched 7 clinical trials in the United States and 11 in other countries using bone marrow-derived mesenchymal stem cell and neural stem cell products. In particular, its mesenchymal stem cells have been approved and listed by the Ministry of Health of Kazakhstan as a treatment of acute myocardial infarction.

Jiuzhitang-ALTACO International Healthcare Center

Responding to calls of the Belt and Road Initiative, Jiuzhitang Co., Ltd. and ALTACO XXI from Kazakhstan jointly built the Jiuzhitang-ALTACO International Healthcare Center in China-Kazakhstan Khorgos International Frontier Cooperation Center. Staring business in September 2019, the center will serve as a platform for innovative cooperation in launching scientific studies on stem cells and translating research findings into clinical practice.